Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors - Full Text View

Purpose

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of cyclophosphamide when given together with combination chemotherapy and a peripheral stem cell transplant in treating patients with malignant solid tumors.

Condition	Intervention	Phase
Brain and Central Nervous System Tumors Childhood Germ Cell Tumor Extragonadal Germ Cell Tumor Liver Cancer Neuroblastoma Ovarian Cancer Sarcoma Testicular Germ Cell Tumor	Biological: filgrastim Drug: carboplatin Drug: cyclophosphamide Drug: etoposide Procedure: autologous bone marrow transplantation Procedure: peripheral blood stem cell transplantation	Phase 1

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WITH HIGH DOSE ETOPOSIDE AND CARBOPLATIN PLUS ESCALATING DOSE CYCLOPHOSPHAMIDE, FOLLOWED BY HEMATOPOIETIC RESCUE USING AUTOLOGOUS CD34+ SELECTED BLOOD STEM CELLS: A PILOT STUDY

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment:	36
Study Start Date:	May 1995

Detailed Description:

OBJECTIVES:

Determine whether autologous transplantation of mobilized CD34+ peripheral blood stem cells (PBSC) can provide complete hematologic reconstitution after myeloablative chemotherapy comprising etoposide (VP-16) and carboplatin (CBDCA) in patients with metastatic or recurrent rhabdomyosarcoma, neuroblastoma, Ewing's sarcoma/primitive neuroectodermal tumor, germ cell tumors, childhood brain tumors, or hepatoblastoma.
Determine the frequency and yield of CD34+ PBSC and granulocyte-macrophage colony-forming units (GM-CFU) that are mobilized, harvested, and purified after a single priming course of high-dose cyclophosphamide (CTX) followed by filgrastim (G-CSF).
Correlate the number of CD34+ cells and GM-CFU in the autologous PBSC graft with time to engraftment of white blood cells, neutrophils, and platelets in these patients.
Determine the optimal day of PBSC harvest after a single priming course of high-dose CTX and G-CSF in these patients.
Determine whether CD34+ PBSC rescue and daily post-transplantation G-CSF decrease the time to hematopoietic recovery after high-dose VP-16 and CBDCA compared to historical results achieved in similar patients rescued with bone marrow.
Compare the tumor cell content of marrow, mobilized blood, and purified CD34+ PBSC graft preparations.
Determine the optimal timing of PBSC mobilization and harvest in relation to extent of prior chemotherapy in these patients.
Determine the feasibility of a single leukapheresis for PBSC harvest in children.
Determine the toxic effects of this regimen in these patients.
Determine the antitumor activity of this regimen in these patients.

OUTLINE: This is a dose-escalation study of cyclophosphamide.

Mobilization/harvest: Patients receive cyclophosphamide IV over 90 minutes on day 0 and filgrastim (G-CSF) subcutaneously or IV over 30 minutes on days 2-15 or until blood counts recover. Peripheral blood stem cells (PBSC) are harvested and selected for CD34+ cells on day 15. Bone marrow is also harvested in case insufficient PBSC are harvested.

Preparative regimen/transplantation: Patients receive carboplatin IV over 1 hour and etoposide IV continuously on days -6 to -4. Cyclophosphamide is administered IV over 1 hour on days -3 and -2 or IV continuously on days -3 and -2, -4 to -2, -5 to -2, or -6 to -2. PBSC or bone marrow is reinfused on day 0.

Cohorts of 3-10 patients receive escalating doses of cyclophosphamide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the highest dose at which 20% of patients experience dose-limiting toxicity.

At least 6 additional patients receive cyclophosphamide at the MTD.

PROJECTED ACCRUAL: A minimum of 36 patients will be accrued for this study.

Eligibility

Ages Eligible for Study:	up to 35 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically proven malignant solid tumor, including any of the following:
- Rhabdomyosarcoma
- Neuroblastoma
- Ewing's sarcoma/primitive neuroectodermal tumor
- Germ cell tumors
- Childhood brain tumors
- Hepatoblastoma
Metastatic disease OR has failed at least first-line therapy
Ineligible for higher priority protocols

PATIENT CHARACTERISTICS:

Age:

Under 36 at transplantation

Performance status:

Karnofsky 60-100%

Life expectancy:

At least 8 weeks

Hematopoietic:

Absolute neutrophil count at least 1,000/mm3
Platelet count at least 75,000/mm3

Hepatic:

Bilirubin no greater than 1.5 mg/dL
Liver function tests no greater than 2 times normal OR
No active hepatitis on liver biopsy
No hepatitis B infection

Renal:

Creatinine no greater than 1.5 mg/dL OR
Glomerular filtration rate (preferably measured) greater than 60% of normal

Cardiovascular:

Left ventricular ejection fraction at least 45%
No active congestive heart failure
No active arrhythmia

Pulmonary:

Age 8 and under: clinically normal pulmonary function
Over age 8: FEV1 and FVC at least 50% predicted
Arterial blood gases normal and DLCO at least 50% if spirograms difficult to
interpret due to poor patient effort, recent surgery, or pulmonary tumor
involvement

Other:

No mucositis or mucosal infection prior to myeloablative chemotherapy
HIV negative
Not pregnant
Negative pregnancy test
Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

See Disease Characteristics

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00007813

Locations

United States, Maryland
Johns Hopkins Oncology Center
Baltimore, Maryland, United States, 21231-2410

Sponsors and Collaborators

Sidney Kimmel Comprehensive Cancer Center

Investigators

Study Chair:

Allen R. Chen, MD, PhD, MHS

Sidney Kimmel Comprehensive Cancer Center

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Publications:

Chen AR, Wiangon S, Noga SJ, et al.: Rapid engraftment of CD34+ selected peripheral blood stem cells (PBSC) after high-dose chemotherapy for patients with recurrent, refractory, or metastatic pediatric solid tumors. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A2038, 530a, 1998.

Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 1998 Nov;22(10):971-9.

Leung W, Chen AR, Klann RC, et al.: Tumor cells frequently detected in marrow and mobilized blood hematopoietic grafts in neuroblastoma and primitive neuroblastoma and primitive neuroectodermal tumor: purging by immunomagnetic CD34+ cell selection. [Abstract] Blood 88: A-1917, 482a, 1996.

Chen AR, Cohen KJ, Eby LL, et al.: Heterogenous mobilization of CD34+ blood stem cells for autologous rescue of children with poor prognosis solid tumors. [Abstract] Blood 86: 403a, 1995.

ClinicalTrials.gov Identifier:	NCT00007813 History of Changes
Other Study ID Numbers:	CDR0000064263, JHOC-9512, NCI-V95-0688
Study First Received:	January 6, 2001
Last Updated:	February 6, 2009
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

recurrent childhood rhabdomyosarcoma
childhood craniopharyngioma
recurrent childhood brain tumor
disseminated neuroblastoma
stage 4S neuroblastoma
recurrent neuroblastoma
stage IV childhood liver cancer
recurrent childhood liver cancer
childhood hepatoblastoma
childhood central nervous system germ cell tumor
stage III malignant testicular germ cell tumor
recurrent malignant testicular germ cell tumor
childhood germ cell tumor
stage IV ovarian germ cell tumor
recurrent ovarian germ cell tumor

extragonadal germ cell tumor
childhood oligodendroglioma
childhood choroid plexus tumor
childhood grade III meningioma
recurrent childhood cerebellar astrocytoma
recurrent childhood cerebral astrocytoma
recurrent childhood medulloblastoma
recurrent childhood visual pathway and hypothalamic glioma
previously treated childhood rhabdomyosarcoma
metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
recurrent childhood ependymoma
childhood teratoma
childhood malignant testicular germ cell tumor
childhood malignant ovarian germ cell tumor

Additional relevant MeSH terms:

Liver Neoplasms
Nervous System Neoplasms
Neuroblastoma
Ovarian Neoplasms
Central Nervous System Neoplasms
Neoplasms, Germ Cell and Embryonal
Neuroectodermal Tumors, Primitive, Peripheral
Sarcoma
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Liver Diseases
Nervous System Diseases
Neuroectodermal Tumors, Primitive

Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Endocrine Gland Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Connective and Soft Tissue
Cyclophosphamide

ClinicalTrials.gov processed this record on May 23, 2013